{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:02:50Z","timestamp":1789164170001,"version":"build-2803163510"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:00:00Z","timestamp":1607385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:00:00Z","timestamp":1607385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2018\/07581-2"],"award-info":[{"award-number":["2018\/07581-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2019\/13229-2"],"award-info":[{"award-number":["2019\/13229-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2016\/12195-9"],"award-info":[{"award-number":["2016\/12195-9"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2013\/11167-3"],"award-info":[{"award-number":["2013\/11167-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2015\/02948-7"],"award-info":[{"award-number":["2015\/02948-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2017\/00624-5"],"award-info":[{"award-number":["2017\/00624-5"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2012\/05178-0"],"award-info":[{"award-number":["2012\/05178-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2013\/08216-2"],"award-info":[{"award-number":["2013\/08216-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Investigations of plasma amino acids in early psychosis and their unaffected siblings are rare. We measured plasma amino acids involved in the co-activation of dopaminergic, GABAergic, glutamatergic, and serotoninergic neurotransmitters in first-episode psychosis (FEP) patients (n\u2009=\u2009166), unaffected siblings (n\u2009=\u200976), and community-based controls (n\u2009=\u2009166) included in a cross-sectional study. Plasma levels of glutamic acid (GLU), glutamine, glycine, proline (PRO), tryptophan (TRP), tyrosine, serine and GABA were quantified by gas-chromatography-mass spectrometry. We used the generalized linear model adjusted by sex, age, and body mass index for group comparison and paired t-test for FEP-Sibling pairs. FEP had reduced GABA plasma levels compared to siblings and controls (p\u2009&lt;\u20090.05 for both). Siblings had lower GLU, Glx and PRO (p\u2009&lt;\u20090.05 for all) but increased TRP compared to patients and controls (p\u2009&lt;\u20090.05 for both). FEP patients with longer duration of pharmacological treatment and medicated only with antipsychotics had increased GLU compared to FEP with shorter periods, or with those treated with a combination of medications (p\u2009&lt;\u20090.05 for both). Finally, FEP patients treated only with antipsychotics presented higher Glx compared to those with mixed medications (p\u2009=\u20090.026). Our study suggests that FEP have low a GABA plasma profile. Unaffected siblings may be a possible risk group for metabolic abnormalities.<\/jats:p>","DOI":"10.1038\/s41598-020-78559-w","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T11:04:42Z","timestamp":1607425482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Plasma amino acids profile in first-episode psychosis, unaffected siblings and community-based controls"],"prefix":"10.1038","volume":"10","author":[{"given":"Camila Marcelino","family":"Loureiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiane Leite","family":"da Roza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Corsi-Zuelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosana","family":"Shuhama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene Aparecida","family":"Fachim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00edvia Maria Cordeiro","family":"Sim\u00f5es-Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Deminice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alceu Afonso","family":"Jord\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Rossi","family":"Menezes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Marta","family":"Del-Ben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Louzada-Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,8]]},"reference":[{"key":"78559_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.neubiorev.2016.03.017","volume":"65","author":"J Davis","year":"2016","unstructured":"Davis, J. et al. A review of vulnerability and risks for schizophrenia: beyond the two hit hypothesis. Neurosci. Biobehav. Rev. 65, 185\u2013194 (2016).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"78559_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1146\/annurev-psych-010416-044053","volume":"68","author":"T Halldorsdottir","year":"2017","unstructured":"Halldorsdottir, T. & Binder, E. B. Gene \u00d7 environment interactions: from molecular mechanisms to behavior. Annu. Rev. Psychol. 68, 215\u2013241 (2017).","journal-title":"Annu. Rev. Psychol."},{"key":"78559_CR3","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/jssc.201400943","volume":"38","author":"DS Domingues","year":"2015","unstructured":"Domingues, D. S. et al. Simultaneous determination of amino acids and neurotransmitters in plasma samples from schizophrenic patients by hydrophilic interaction liquid chromatography with tandem mass spectrometry. J. Sep. Sci. 38, 780\u2013787 (2015).","journal-title":"J. Sep. Sci."},{"key":"78559_CR4","first-page":"63","volume":"11","author":"S Saleem","year":"2017","unstructured":"Saleem, S., Shaukat, F., Gul, A., Arooj, M. & Malik, A. Potential role of amino acids in pathogenesis of schizophrenia. Int. J. Health Sci. (Qassim) 11, 63\u201368 (2017).","journal-title":"Int. J. Health Sci. (Qassim)"},{"key":"78559_CR5","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1042\/BCJ20160822","volume":"474","author":"S Br\u00f6er","year":"2017","unstructured":"Br\u00f6er, S. & Br\u00f6er, A. Amino acid homeostasis and signalling in mammalian cells and organisms. Biochem. J. 474, 1935\u20131963 (2017).","journal-title":"Biochem. J."},{"key":"78559_CR6","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1177\/0148607115624084","volume":"40","author":"LJ Hoffer","year":"2014","unstructured":"Hoffer, L. J. Human protein and amino acid requirements. J. Parenter. Enter. Nutr. 40, 460\u2013474 (2014).","journal-title":"J. Parenter. Enter. Nutr."},{"key":"78559_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.phrs.2018.05.014","volume":"133","author":"Y Shimomura","year":"2018","unstructured":"Shimomura, Y. & Kitaura, Y. Physiological and pathological roles of branched-chain amino acids in the regulation of protein and energy metabolism and neurological functions. Pharmacol. Res. 133, 215\u2013217 (2018).","journal-title":"Pharmacol. Res."},{"key":"78559_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00726-009-0269-0","volume":"37","author":"G Wu","year":"2009","unstructured":"Wu, G. Amino acids: metabolism, functions, and nutrition. Amino Acids 37, 1\u201317 (2009).","journal-title":"Amino Acids"},{"key":"78559_CR9","doi-asserted-by":"publisher","first-page":"593","DOI":"10.5483\/BMBRep.2010.43.9.593","volume":"43","author":"YK Choi","year":"2010","unstructured":"Choi, Y. K. & Tarazi, F. I. Alterations in dopamine and glutamate neurotransmission in tetrahydrobiopterin deficient spr-\/-mice: relevance to schizophrenia. BMB Rep. 43, 593\u2013598 (2010).","journal-title":"BMB Rep."},{"key":"78559_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.csbj.2016.02.003","volume":"14","author":"R Zhang","year":"2016","unstructured":"Zhang, R. et al. Metabolomic profiling of post-mortem brain reveals changes in amino acid and glucose metabolism in mental illness compared with controls. Comput. Struct. Biotechnol. J. 14, 106\u2013116 (2016).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"78559_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41537-017-0015-7","volume":"3","author":"T Nuzzo","year":"2017","unstructured":"Nuzzo, T. et al. Decreased free d-aspartate levels are linked to enhanced d-aspartate oxidase activity in the dorsolateral prefrontal cortex of schizophrenia patients. NPJ Schizophr. 3, 16 (2017).","journal-title":"NPJ Schizophr."},{"key":"78559_CR12","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/sj.mp.4002000","volume":"12","author":"R Kaddurah-Daouk","year":"2007","unstructured":"Kaddurah-Daouk, R. et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol. Psychiatry 12, 934\u2013945 (2007).","journal-title":"Mol. Psychiatry"},{"key":"78559_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.dsx.2017.11.006","volume":"12","author":"S Anjum","year":"2018","unstructured":"Anjum, S., Bathla, M., Panchal, S., Singh, G. P. & Singh, M. Metabolic syndrome in drug na\u00efve schizophrenic patients. Diabetes Metab. Syndr. Clin. Res. Rev. 12, 135\u2013140 (2018).","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"78559_CR14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12967-015-0540-y","volume":"13","author":"M-L Liu","year":"2015","unstructured":"Liu, M.-L. et al. Severe disturbance of glucose metabolism in peripheral blood mononuclear cells of schizophrenia patients: a targeted metabolomic study. J. Transl. Med. 13, 226 (2015).","journal-title":"J. Transl. Med."},{"key":"78559_CR15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.4103\/0022-3859.90075","volume":"57","author":"V Mohan","year":"2011","unstructured":"Mohan, V., Subashini, R., Padmavati, R., Deepa, M. & Thara, R. Prevalence of diabetes, obesity, and metabolic syndrome in subjects with and without schizophrenia (CURES-104). J. Postgrad. Med. 57, 272 (2011).","journal-title":"J. Postgrad. Med."},{"key":"78559_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fpsyt.2018.00155","volume":"9","author":"L Leppik","year":"2018","unstructured":"Leppik, L. et al. Profiling of amino acids and their derivatives biogenic amines before and after antipsychotic treatment in first-episode psychosis. Front. Psychiatry 9, 155 (2018).","journal-title":"Front. Psychiatry"},{"key":"78559_CR17","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00726-018-2579-6","volume":"50","author":"B Cao","year":"2018","unstructured":"Cao, B. et al. Characterizing amino-acid biosignatures amongst individuals with schizophrenia: a case-control study. Amino Acids 50, 1013\u20131023 (2018).","journal-title":"Amino Acids"},{"key":"78559_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.schres.2017.09.021","volume":"195","author":"J Davison","year":"2018","unstructured":"Davison, J., O\u2019Gorman, A., Brennan, L. & Cotter, D. R. A systematic review of metabolite biomarkers of schizophrenia. Schizophr. Res. 195, 32\u201350 (2018).","journal-title":"Schizophr. Res."},{"key":"78559_CR19","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/ajmg.b.32662","volume":"177","author":"C Li","year":"2018","unstructured":"Li, C. et al. Metabolomics in patients with psychosis: a systematic review. Am. J. Med. Genet. B Neuropsychiatr. Genet. 177, 580\u2013588 (2018).","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"78559_CR20","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1038\/s41598-017-02267-1","volume":"7","author":"T Nagai","year":"2017","unstructured":"Nagai, T. et al. Reduced mismatch negativity is associated with increased plasma level of glutamate in first-episode psychosis. Sci. Rep. 7, 2258 (2017).","journal-title":"Sci. Rep."},{"key":"78559_CR21","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1073\/pnas.1315034111","volume":"111","author":"L Gong","year":"2014","unstructured":"Gong, L. et al. Sumoylation differentially regulates Sp1 to control cell differentiation. Proc. Natl. Acad. Sci. U.S.A. 111, 5574\u20135579 (2014).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"78559_CR22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3389\/fpsyt.2018.00713","volume":"9","author":"C Madeira","year":"2018","unstructured":"Madeira, C. et al. Blood levels of glutamate and glutamine in recent onset and chronic schizophrenia. Front. Psychiatry 9, 713 (2018).","journal-title":"Front. Psychiatry"},{"key":"78559_CR23","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.pnpbp.2008.07.022","volume":"32","author":"T Ohnuma","year":"2008","unstructured":"Ohnuma, T. et al. Changes in plasma glycine, l-serine, and d-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP). Prog. Neuro-Psychopharmacol. Biol. Psychiatry 32, 1905\u20131912 (2008).","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"78559_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/978-3-319-55769-4_4","volume":"16","author":"F Zafra","year":"2017","unstructured":"Zafra, F. et al. Glycine transporters and its coupling with NMDA receptors. Adv. Neurobiol. 16, 55\u201383 (2017).","journal-title":"Adv. Neurobiol."},{"key":"78559_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s11064-014-1473-1","volume":"40","author":"AB Walls","year":"2015","unstructured":"Walls, A. B., Waagepetersen, H. S., Bak, L. K., Schousboe, A. & Sonnewald, U. The glutamine\u2013glutamate\/GABA cycle: function, regional differences in glutamate and GABA production and effects of interference with GABA metabolism. Neurochem. Res. 40, 402\u2013409 (2015).","journal-title":"Neurochem. Res."},{"key":"78559_CR26","doi-asserted-by":"publisher","first-page":"e0196283","DOI":"10.1371\/journal.pone.0196283","volume":"13","author":"P Cappelletti","year":"2018","unstructured":"Cappelletti, P. et al. Proline oxidase controls proline, glutamate, and glutamine cellular concentrations in a U87 glioblastoma cell line. PLoS ONE 13, e0196283 (2018).","journal-title":"PLoS ONE"},{"key":"78559_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1017\/S1461145705005638","volume":"9","author":"L Bjerkenstedt","year":"2005","unstructured":"Bjerkenstedt, L. et al. Support for limited brain availability of tyrosine in patients with schizophrenia. Int. J. Neuropsychopharmacol. 9, 247\u2013255 (2005).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"78559_CR28","doi-asserted-by":"publisher","first-page":"117864691775342","DOI":"10.1177\/1178646917753422","volume":"11","author":"AA-B Badawy","year":"2018","unstructured":"Badawy, A.A.-B. Modulation of tryptophan and serotonin metabolism as a biochemical basis of the behavioral effects of use and withdrawal of androgenic-anabolic steroids and other image- and performance-enhancing agents. Int. J. Tryptophan Res. 11, 1178646917753422 (2018).","journal-title":"Int. J. Tryptophan Res."},{"key":"78559_CR29","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1192\/bjp.2019.110","volume":"215","author":"CM Del-Ben","year":"2019","unstructured":"Del-Ben, C. M. et al. Urbanicity and risk of first-episode psychosis: incidence study in Brazil. Br. J. Psychiatry 215, 726\u2013729 (2019).","journal-title":"Br. J. Psychiatry"},{"key":"78559_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/jamapsychiatry.2017.3554","volume":"75","author":"HE Jongsma","year":"2018","unstructured":"Jongsma, H. E. et al. Treated incidence of psychotic disorders in the multinational EU-GEI study. JAMA Psychiatry 75, 36 (2018).","journal-title":"JAMA Psychiatry"},{"key":"78559_CR31","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1093\/schbul\/sbu069","volume":"40","author":"European Network of National Networks studying Gene-Environment Interactions in Schizophrenia (EU-GEI)","year":"2014","unstructured":"European Network of National Networks studying Gene-Environment Interactions in Schizophrenia (EU-GEI) et al. Identifying Gene-environment interactions in Schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr. Bull. 40, 729\u2013736 (2014).","journal-title":"Schizophr. Bull."},{"key":"78559_CR32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.schres.2018.06.037","volume":"202","author":"CM Loureiro","year":"2018","unstructured":"Loureiro, C. M. et al. Low plasma concentrations of N -methyl-d-aspartate receptor subunits as a possible biomarker for psychosis. Schizophr. Res. 202, 55\u201363 (2018).","journal-title":"Schizophr. Res."},{"key":"78559_CR33","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1590\/S1516-44462001000300008","volume":"23","author":"CM Del-Ben","year":"2001","unstructured":"Del-Ben, C. M. et al. Confiabilidade da \u2018Entrevista Cl\u00ednica Estruturada para o DSM-IV\u2014Vers\u00e3o Cl\u00ednica\u2019 traduzida para o portugu\u00eas. Rev. Bras. Psiquiatr. 23, 156\u2013159 (2001).","journal-title":"Rev. Bras. Psiquiatr."},{"key":"78559_CR34","volume-title":"Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Clinical Version (SCID-CV)","author":"MB First","year":"1997","unstructured":"First, M. B., Spitzer, R. L., Gibbon, M. & Williams, J. B. W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Clinical Version (SCID-CV) (Biometrics Research, New York State Psychiatric Institute, New York, 1997)."},{"key":"78559_CR35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2217\/epi-2018-0127","volume":"11","author":"HA Fachim","year":"2019","unstructured":"Fachim, H. A. et al. GRIN2B promoter methylation deficits in early-onset schizophrenia and its association with cognitive function. Epigenomics 11, 401\u2013410 (2019).","journal-title":"Epigenomics"},{"key":"78559_CR36","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1017\/S0033291719001016","volume":"50","author":"F Corsi-Zuelli","year":"2019","unstructured":"Corsi-Zuelli, F. et al. Cytokine profile in first-episode psychosis, unaffected siblings and community-based controls: the effects of familial liability and childhood maltreatment. Psychol. Med. 50, 1139\u20131147 (2019).","journal-title":"Psychol. Med."},{"key":"78559_CR37","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1034\/j.1600-0447.2001.00185.x","volume":"103","author":"JA Crippa","year":"2001","unstructured":"Crippa, J. A., Sanches, R. F., Hallak, J. E., Loureiro, S. R. & Zuardi, A. W. A structured interview guide increases brief psychiatric rating scale reliability in raters with low clinical experience. Acta Psychiatr. Scand. 103, 465\u2013470 (2001).","journal-title":"Acta Psychiatr. Scand."},{"key":"78559_CR38","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall, J. E. & Gorham, D. R. The brief psychiatric rating scale. Psychol. Rep. 10, 799\u2013812 (1962).","journal-title":"Psychol. Rep."},{"key":"78559_CR39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.schres.2005.04.018","volume":"80","author":"SP Singh","year":"2005","unstructured":"Singh, S. P. et al. Determining the chronology and components of psychosis onset: the Nottingham onset schedule (NOS). Schizophr. Res. 80, 117\u2013130 (2005).","journal-title":"Schizophr. Res."},{"key":"78559_CR40","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/chromsci\/7.10.604","volume":"7","author":"E Gelpi","year":"1969","unstructured":"Gelpi, E., Koenig, W. A., Gibert, J. & Oro, J. Combined gas chromatography-mass spectrometry of amino acid derivatives. J. Chromatogr. Sci. 7, 604\u2013613 (1969).","journal-title":"J. Chromatogr. Sci."},{"key":"78559_CR41","volume-title":"SAS Language: Reference: Version 94","author":"SAS Institute, Statistical Analysis System Institute (Cary, & NC)","year":"2013","unstructured":"SAS Institute, Statistical Analysis System Institute (Cary, & NC). SAS Language: Reference: Version 94 (SAS Institute, Cary, 2013)."},{"key":"78559_CR42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/gm233","volume":"3","author":"M Ore\u0161i\u010d","year":"2011","unstructured":"Ore\u0161i\u010d, M. et al. Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Med. 3, 19 (2011).","journal-title":"Genome Med."},{"key":"78559_CR43","doi-asserted-by":"publisher","first-page":"13983","DOI":"10.1038\/s41598-020-71014-w","volume":"10","author":"M Parksepp","year":"2020","unstructured":"Parksepp, M. et al. Metabolomics approach revealed robust changes in amino acid and biogenic amine signatures in patients with schizophrenia in the early course of the disease. Sci. Rep. 10, 13983 (2020).","journal-title":"Sci. Rep."},{"key":"78559_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-47761-w","volume":"9","author":"WW Labaki","year":"2019","unstructured":"Labaki, W. W. et al. Serum amino acid concentrations and clinical outcomes in smokers: SPIROMICS metabolomics study. Sci. Rep. 9, 1\u20139 (2019).","journal-title":"Sci. Rep."},{"key":"78559_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-3242-6","volume-title":"Generalized Linear Models","author":"P McCullagh","year":"1989","unstructured":"McCullagh, P. & Nelder, J. A. Generalized Linear Models 2nd edn. (Chapman & Hall, London, 1989).","edition":"2"},{"key":"78559_CR46","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"J Cohen","year":"1988","unstructured":"Cohen, J. Statistical Power Analysis for the Behavioral Sciences (Lawrence Erlbaum Associates, New York, 1988)."},{"key":"78559_CR47","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3389\/fpsyg.2013.00863","volume":"4","author":"D Lakens","year":"2013","unstructured":"Lakens, D. Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front. Psychol. 4, 863 (2013).","journal-title":"Front. Psychol."},{"key":"78559_CR48","first-page":"111","volume":"361","author":"KO McGraw","year":"1992","unstructured":"McGraw, K. O. & Seok, P. W. A common language effect size statistic. Psychol. Bull. 361, 111 (1992).","journal-title":"Psychol. Bull."},{"key":"78559_CR49","unstructured":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 894:i-xii, 1\u2013253 (2000)."},{"key":"78559_CR50","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.biopsych.2016.04.007","volume":"81","author":"KN Thakkar","year":"2017","unstructured":"Thakkar, K. N. et al. 7T proton magnetic resonance spectroscopy of gamma-aminobutyric acid, glutamate, and glutamine reveals altered concentrations in patients with schizophrenia and healthy siblings. Biol. Psychiatry 81, 525\u2013535 (2017).","journal-title":"Biol. Psychiatry"},{"key":"78559_CR51","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neulet.2016.11.051","volume":"637","author":"M \u0130lhan Atag\u00fcn","year":"2018","unstructured":"\u0130lhan Atag\u00fcn, M. et al. Perisylvian GABA levels in schizophrenia and bipolar disorder. Neurosci. Lett. 637, 70\u201374 (2018).","journal-title":"Neurosci. Lett."},{"key":"78559_CR52","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.pnpbp.2010.07.006","volume":"34","author":"H-LL Cai","year":"2010","unstructured":"Cai, H.-L.L. et al. Elevated plasma \u03b3-aminobutyrate\/glutamate ratio and responses to risperidone antipsychotic treatment in schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 34, 1273\u20131278 (2010).","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"78559_CR53","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s11064-009-0048-z","volume":"35","author":"A Arr\u00fae","year":"2010","unstructured":"Arr\u00fae, A. et al. GABA and homovanillic acid in the plasma of schizophrenic and bipolar i patients. Neurochem. Res. 35, 247\u2013253 (2010).","journal-title":"Neurochem. Res."},{"key":"78559_CR54","doi-asserted-by":"publisher","first-page":"78728","DOI":"10.1039\/C5RA14058G","volume":"5","author":"Y Wang","year":"2015","unstructured":"Wang, Y., Liu, S., Hu, Y., Li, P. & Wan, J.-B. Current state of the art of mass spectrometry-based metabolomics studies-a review focusing on wide coverage, high throughput and easy identification. RSC Adv. 5, 78728\u201378737 (2015).","journal-title":"RSC Adv."},{"key":"78559_CR55","doi-asserted-by":"publisher","first-page":"062","DOI":"10.1093\/ijnp\/pyw062","volume":"19","author":"PL Gaskin","year":"2016","unstructured":"Gaskin, P. L., Toledo-Rodriguez, M., Alexander, S. P. & Fone, K. C. Down-regulation of hippocampal genes regulating dopaminergic, gabaergic, and glutamatergic function following combined neonatal phencyclidine and post-weaning social isolation of rats as a neurodevelopmental model for schizophrenia. Int. J. Neuropsychopharmacol. 19, 062 (2016).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"78559_CR56","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nrn1648","volume":"6","author":"DA Lewis","year":"2005","unstructured":"Lewis, D. A., Hashimoto, T. & Volk, D. W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 6, 312\u2013324 (2005).","journal-title":"Nat. Rev. Neurosci."},{"key":"78559_CR57","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.tics.2015.09.009","volume":"19","author":"TD Cannon","year":"2015","unstructured":"Cannon, T. D. How schizophrenia develops: cognitive and brain mechanisms underlying onset of psychosis. Trends Cogn. Sci. 19, 744\u2013756 (2015).","journal-title":"Trends Cogn. Sci."},{"key":"78559_CR58","first-page":"1","volume":"2016","author":"JJ Wang","year":"2016","unstructured":"Wang, J. J. et al. Reduced \u03b3-aminobutyric acid and glutamate+glutamine levels in drug-naive patients with first-episode schizophrenia but not in those at ultrahigh risk. Neural Plast. 2016, 1\u20139 (2016).","journal-title":"Neural Plast."},{"key":"78559_CR59","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.biopsych.2017.09.028","volume":"83","author":"C de la Fuente-Sandoval","year":"2018","unstructured":"de la Fuente-Sandoval, C. et al. Prefrontal and striatal gamma-aminobutyric acid levels and the effect of antipsychotic treatment in first-episode psychosis patients. Biol. Psychiatry 83, 475\u2013483 (2018).","journal-title":"Biol. Psychiatry"},{"key":"78559_CR60","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41398-018-0261-0","volume":"8","author":"D Koshiyama","year":"2018","unstructured":"Koshiyama, D. et al. Electrophysiological evidence for abnormal glutamate-GABA association following psychosis onset. Transl. Psychiatry 8, 211 (2018).","journal-title":"Transl. Psychiatry"},{"key":"78559_CR61","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.schres.2014.12.026","volume":"167","author":"SM Cohen","year":"2015","unstructured":"Cohen, S. M., Tsien, R. W., Goff, D. C. & Halassa, M. M. The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia. Schizophr. Res. 167, 98\u2013107 (2015).","journal-title":"Schizophr. Res."},{"key":"78559_CR62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fpsyt.2016.00061","volume":"7","author":"C Chiapponi","year":"2016","unstructured":"Chiapponi, C., Piras, F., Piras, F., Caltagirone, C. & Spalletta, G. GABA system in schizophrenia and mood disorders: a mini review on third-generation imaging studies. Front. Psychiatry 7, 61 (2016).","journal-title":"Front. Psychiatry"},{"key":"78559_CR63","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/BF00445551","volume":"99","author":"G Alfredsson","year":"1989","unstructured":"Alfredsson, G. & Wiesel, F. A. Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology 99, 322\u2013327 (1989).","journal-title":"Psychopharmacology"},{"key":"78559_CR64","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.schres.2007.06.012","volume":"95","author":"A Palomino","year":"2007","unstructured":"Palomino, A. et al. Decreased levels of plasma glutamate in patients with first-episode schizophrenia and bipolar disorder. Schizophr. Res. 95, 174\u2013178 (2007).","journal-title":"Schizophr. Res."},{"key":"78559_CR65","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.neulet.2014.08.052","volume":"582","author":"H Yamamori","year":"2014","unstructured":"Yamamori, H. et al. Changes in plasma d-serine, l-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment. Neurosci. Lett. 582, 93\u201398 (2014).","journal-title":"Neurosci. Lett."},{"key":"78559_CR66","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1176\/appi.ajp.162.9.1738","volume":"162","author":"G Neeman","year":"2005","unstructured":"Neeman, G. et al. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am. J. Psychiatry 162, 1738\u20131740 (2005).","journal-title":"Am. J. Psychiatry"},{"key":"78559_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1461145703003900","volume":"7","author":"T Sumiyoshi","year":"2004","unstructured":"Sumiyoshi, T. et al. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int. J. Neuropsychopharmacol. 7, 1\u20138 (2004).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"78559_CR68","doi-asserted-by":"publisher","first-page":"22127","DOI":"10.1002\/syn.22127","volume":"73","author":"B Garip","year":"2019","unstructured":"Garip, B. & Kayir, H. Alteration in NMDAR-related amino acids in first episode psychosis. Synapse 73, 22127 (2019).","journal-title":"Synapse"},{"key":"78559_CR69","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/mp.2008.87","volume":"15","author":"ES Lutkenhoff","year":"2010","unstructured":"Lutkenhoff, E. S. et al. Proton MRS in twin pairs discordant for schizophrenia. Mol. Psychiatry 15, 308\u2013318 (2010).","journal-title":"Mol. Psychiatry"},{"key":"78559_CR70","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.schres.2007.11.028","volume":"99","author":"SE Purdon","year":"2008","unstructured":"Purdon, S. E., Valiakalayil, A., Hanstock, C. C., Seres, P. & Tibbo, P. Elevated 3T proton MRS glutamate levels associated with poor continuous performance test (CPT-0X) scores and genetic risk for schizophrenia. Schizophr Res. 99, 218\u2013224 (2008).","journal-title":"Schizophr Res."},{"key":"78559_CR71","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.mehy.2018.06.022","volume":"118","author":"A W\u0142odarczyk","year":"2018","unstructured":"W\u0142odarczyk, A., Wiglusz, M. S. & Cuba\u0142a, W. J. Ketogenic diet for schizophrenia: nutritional approach to antipsychotic treatment. Med. Hypotheses 118, 74\u201377 (2018).","journal-title":"Med. Hypotheses"},{"key":"78559_CR72","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00726-017-2393-6","volume":"49","author":"L Gracia-Marco","year":"2017","unstructured":"Gracia-Marco, L. et al. Amino acids intake and physical fitness among adolescents. Amino Acids 49, 1041\u20131052 (2017).","journal-title":"Amino Acids"},{"key":"78559_CR73","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/mnfr.201200629","volume":"57","author":"C Morris","year":"2013","unstructured":"Morris, C. et al. The relationship between aerobic fitness level and metabolic profiles in healthy adults. Mol. Nutr. Food Res. 57, 1246\u20131254 (2013).","journal-title":"Mol. Nutr. Food Res."},{"key":"78559_CR74","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4306\/pi.2008.5.4.203","volume":"5","author":"V De Luca","year":"2008","unstructured":"De Luca, V. et al. Peripheral amino acid levels in schizophrenia and antipsychotic treatment. Psychiatry Investig. 5, 203 (2008).","journal-title":"Psychiatry Investig."},{"key":"78559_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399406000068","volume":"8","author":"JP Ruddick","year":"2006","unstructured":"Ruddick, J. P. et al. Tryptophan metabolism in the central nervous system: medical implications. Expert Rev. Mol. Med. 8, 1\u201327 (2006).","journal-title":"Expert Rev. Mol. Med."},{"key":"78559_CR76","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3389\/fphys.2020.00973","volume":"11","author":"R Zaragoz\u00e1","year":"2020","unstructured":"Zaragoz\u00e1, R. Transport of amino acids across the blood-brain barrier. Front. Physiol. 11, 973 (2020).","journal-title":"Front. Physiol."},{"key":"78559_CR77","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neulet.2016.10.006","volume":"634","author":"SE Cho","year":"2016","unstructured":"Cho, S. E., Na, K. S., Cho, S. J. & Kang, S. G. Low D-serine levels in schizophrenia: a systematic review and meta-analysis. Neurosci. Lett. 634, 42\u201351 (2016).","journal-title":"Neurosci. Lett."},{"key":"78559_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/0471142727.mb3004s114","volume":"114","author":"O Fiehn","year":"2016","unstructured":"Fiehn, O. & Edu, O. Metabolomics by gas chromatography-mass spectrometry: the combination of targeted and untargeted profiling. Curr. Protoc. Mol. Biol. 114, 1\u201332 (2016).","journal-title":"Curr. Protoc. Mol. Biol."},{"key":"78559_CR79","volume-title":"Mass Spectrometry for the Clinical Laboratory","author":"H Nair","year":"2016","unstructured":"Nair, H. & Clarke, W. Mass Spectrometry for the Clinical Laboratory 1st edn. (Academic Press, Cambridge, 2016).","edition":"1"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78559-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78559-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78559-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:19:27Z","timestamp":1670372367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78559-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,8]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["78559"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-78559-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,8]]},"assertion":[{"value":"10 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21423"}}